TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC).

被引：0
|
作者：
von Minckwitz, G. [1 ]
Cortes, J. [1 ]
Gligorov, J. [1 ]
Marschner, N. W. [1 ]
Puglisi, F. [1 ]
Vrdoljak, E. [1 ]
Duenne, A-A [1 ]
Zielinski, C. [1 ]
机构：
[1] GBG Forsch GmbH, German Breast Grp, Neu Isenburg, Germany
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-OT3-01-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-01-04
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Gligorov, Joseph
    Marschner, Norbert
    Zielinski, Christoph
    de Laurentiis, Michele
    Brain, Etienne
    Levy, Christelle
    Welt, Anja
    Kahan, Zsuzsanna
    Inbar, Moshe
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
  • [2] Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez-Martin, A.
    Ebel, K.
    Easton, V.
    von Minckwitz, G.
    CANCER RESEARCH, 2016, 76
  • [3] Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)
    Cortes, Javier
    Vrdoljak, Eduard
    Puglisi, Fabio
    Marschner, Norbert
    Gligorov, Joseph
    Zielinski, Christoph
    Villanueva, Cristian
    Romieu, Gilles
    Lang, Istvan
    Ciruelos, Eva
    Veyret, Corinne
    Fontana, Andrea
    Oestergaard, Mikkel
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
  • [4] Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC)
    Robert, Nicholas J.
    Dieras, Veronique
    Jackisch, Christian
    Srock, Stefanie
    Freudensprung, Ulrich
    Faoro, Leonardo
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2014, 74 (19)
  • [5] Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C.
    Gligorov, J.
    Marschner, N.
    Puglisi, F.
    Vrdoljak, E.
    Castan, J. Cortes
    de Ducla, S.
    Deurloo, R.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] BEVACIZUMAB-CAPECITABINE (BEV-CAP) AFTER INITIAL 1ST-LINE BEVACIZUMAB-DOCETAXEL (BEV-DOC) IN PATIENTS (PTS) WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): SAFETY ANALYSIS OF THE IMELDA TRIAL
    Gligorov, J.
    Alba-Conejo, E.
    Bines, J.
    Cortes, P. A.
    Doval, D. C.
    Jiang, Z.
    Freudensprung, U.
    Mustacchi, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 128 - 128
  • [7] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
    Lang, I.
    Inbar, M.
    Steger, G.
    Greil, R.
    Zvirbule, Z.
    Beslija, S.
    Kahan, Z.
    Taskova, V.
    Kaufmann, B.
    Zielinski, C. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 278
  • [8] BIOMARKER (BM) RESULTS FROM THE PHASE III AVEREL TRIAL OF 1ST-LINE BEVACIZUMAB (BV), TRASTUZUMAB (H) plus DOCETAXEL (T) FOR HER2-POSITIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC)
    Gianni, L.
    Chan, A.
    Mansutti, M.
    Pivot, X.
    Greil, R.
    Provencher, L.
    Prot, S.
    Moore, N.
    Scherer, S. J.
    Pallaud, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 531 - 532
  • [9] Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).
    Arnold, Dirk
    Andre, Thierry
    Bennouna, Jaafar
    Sastre, Javier
    Osterlund, Pia J.
    Greil, Richard
    Van Cutsem, Eric
    Von Moos, Roger
    Reyes-Rivera, Irmarie
    Bendahmane, Belguendouz
    Kubicka, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)
    Lang, I.
    Inbar, M.
    Greil, R.
    Kahan, Z.
    Beslija, S.
    Steger, G. G.
    Stemmer, S. M.
    Zvribule, Z.
    Kaufman, B.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
12345